Apolipoprotein B signal peptide polymorphism in patients with myocardial infarction and controls. "The ECTIM study". 1993

S Visvikis, and J P Cambou, and D Arveiler, and A E Evans, and H J Parra, and D Aguillon, and J C Fruchart, and G Siest, and F Cambien
Laboratoire du Centre de Médecine Préventive, UA CNRS N. 597, Vandoeuvre lès Nancy, France.

We report the allele frequencies of the apolipoprotein B (Apo B) signal peptide polymorphism in patients with myocardial infarction and compare them with controls. The first sample consists of 197 myocardial infarction patients and 168 controls from Belfast (UK). The second sample consists of 167 myocardial infarction patients and 205 controls from Strasbourg (France), and the third consists of 71 patients and 146 controls from Haute-Garonne (Toulouse, France). No significant differences were observed in the frequency distribution of genotypes among cases and controls or between populations. However, there were more rare homozygotes in the Belfast cases. Significant associations were observed between the Apo B signal peptide polymorphism and mean levels of total cholesterol, low density lipoprotein cholesterol, Apo B and lipoprotein particles containing Apo (a) [Lp(a)] in the Strasbourg control population. Individuals homozygous for the rare allele had higher levels of these lipid parameters. In Belfast, although not statistically significant, the Apo B signal peptide polymorphism had a similar effect on Apo-B-related parameters as seen in Strasbourg. No significant associations were observed in the Haute-Garonne population where the risk of myocardial infarction is three times lower than in Belfast. In all three populations, the average Lp(a) levels were consistently different among Apo B signal peptide genotypes. These data implicate the Apo B signal peptide in determining some of the risks of myocardial infarction in these populations. Regardless of the exact mechanism, the Apo B signal peptide is an important candidate locus for the study of potentially atherogenic lipid variants.

UI MeSH Term Description Entries
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D009660 Northern Ireland The northern one-sixth of the island of Ireland - between the North Atlantic Ocean and the North Sea; northwest of France. The capital is Belfast.
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA

Related Publications

S Visvikis, and J P Cambou, and D Arveiler, and A E Evans, and H J Parra, and D Aguillon, and J C Fruchart, and G Siest, and F Cambien
May 1992, Human genetics,
S Visvikis, and J P Cambou, and D Arveiler, and A E Evans, and H J Parra, and D Aguillon, and J C Fruchart, and G Siest, and F Cambien
May 1994, Clinical genetics,
S Visvikis, and J P Cambou, and D Arveiler, and A E Evans, and H J Parra, and D Aguillon, and J C Fruchart, and G Siest, and F Cambien
November 1998, Atherosclerosis,
S Visvikis, and J P Cambou, and D Arveiler, and A E Evans, and H J Parra, and D Aguillon, and J C Fruchart, and G Siest, and F Cambien
January 2008, Clinical chemistry and laboratory medicine,
S Visvikis, and J P Cambou, and D Arveiler, and A E Evans, and H J Parra, and D Aguillon, and J C Fruchart, and G Siest, and F Cambien
September 1994, Arteriosclerosis and thrombosis : a journal of vascular biology,
S Visvikis, and J P Cambou, and D Arveiler, and A E Evans, and H J Parra, and D Aguillon, and J C Fruchart, and G Siest, and F Cambien
July 1987, The New England journal of medicine,
S Visvikis, and J P Cambou, and D Arveiler, and A E Evans, and H J Parra, and D Aguillon, and J C Fruchart, and G Siest, and F Cambien
August 1995, Atherosclerosis,
S Visvikis, and J P Cambou, and D Arveiler, and A E Evans, and H J Parra, and D Aguillon, and J C Fruchart, and G Siest, and F Cambien
June 1994, Zhonghua yi xue za zhi,
S Visvikis, and J P Cambou, and D Arveiler, and A E Evans, and H J Parra, and D Aguillon, and J C Fruchart, and G Siest, and F Cambien
December 1999, Human biology,
S Visvikis, and J P Cambou, and D Arveiler, and A E Evans, and H J Parra, and D Aguillon, and J C Fruchart, and G Siest, and F Cambien
June 1989, European journal of clinical investigation,
Copied contents to your clipboard!